Research programme: neurological disorders therapies - Lexicon Pharmaceuticals/Bristol-Myers SquibbAlternative Names: LG 262; LG 317; LG 324; LG 351; LG 451; LG 470; LG 487; LG 527; LG 590; LG 726; LG 752; LG 852; LG 915; LX 9211
Latest Information Update: 18 Nov 2016
At a glance
- Originator Bristol-Myers Squibb; Lexicon Genetics
- Developer Bristol-Myers Squibb; Lexicon Pharmaceuticals
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neurological disorders; Neuropathic pain